Literature DB >> 27500095

Imaging of coronary atherosclerosis in various susceptible groups.

Ravi Kiran Munnur1, Nitesh Nerlekar1, Dennis T L Wong1.   

Abstract

Coronary artery disease (CAD) is the leading cause of death and disability worldwide. Atherosclerosis, which is the primary pathophysiologic mechanism for the development of plaque leading to CAD, is a multifactorial process resulting from a complex interplay between genetic susceptibility and various risk factors such as hypertension (HT), dyslipidaemia, diabetes mellitus (DM) and smoking. In addition, influences from other disease states such as chronic kidney disease (CKD), obesity and the metabolic syndrome as well as gender and ethnic diversity also contribute to the disease process. Insights from pathological observations and advances in cellular and molecular biology have helped us understand the process of plaque formation, progression and rupture leading to events. Several intravascular imaging techniques such as intravascular ultrasound (IVUS), Virtual histology IVUS (VH-IVUS) and optical coherence tomography (OCT) allow in vivo assessment of plaque burden, plaque morphology and response to therapy. In addition, non invasive assessment using coronary artery calcium (CAC) score allows risk stratification and plaque burden assessment whilst computed tomography coronary angiography (CTCA) allows evaluation of luminal stenosis, plaque characterisation and quantification. This review aims to summarise the results of invasive and non-invasive imaging studies of coronary atherosclerosis seen in various high-risk populations including DM, metabolic syndrome, obesity, CKD and, gender differences and ethnicity. Understanding the phenotype of plaques in various susceptible groups may allow potential development of personalised therapies.

Entities:  

Keywords:  Coronary artery disease (CAD); atherosclerosis; computed tomography coronary angiography (CTCA); coronary artery calcium score; intravascular ultrasound (IVUS); optical coherence tomography (OCT)

Year:  2016        PMID: 27500095      PMCID: PMC4960067          DOI: 10.21037/cdt.2016.03.02

Source DB:  PubMed          Journal:  Cardiovasc Diagn Ther        ISSN: 2223-3652


  106 in total

1.  Oxidized low-density lipoprotein and atherosclerosis.

Authors:  Daniel Steinberg; Joseph L Witztum
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-12       Impact factor: 8.311

2.  Progression of subclinical coronary atherosclerosis: does obesity make a difference?

Authors:  Andrea E Cassidy; Lawrence F Bielak; Yan Zhou; Patrick F Sheedy; Stephen T Turner; Jerome F Breen; Philip A Araoz; Iftikhar J Kullo; Xihong Lin; Patricia A Peyser
Journal:  Circulation       Date:  2005-04-19       Impact factor: 29.690

3.  Comparison of coronary atherosclerotic volume in patients with glomerular filtration rates < or = 60 versus > 60 ml/min/1.73 m(2): a meta-analysis of intravascular ultrasound studies.

Authors:  Stephen J Nicholls; E Murat Tuzcu; Amy Hsu; Kathy Wolski; Ilke Sipahi; Paul Schoenhagen; Timothy Crowe; Samir R Kapadia; Stanley L Hazen; Steven E Nissen
Journal:  Am J Cardiol       Date:  2007-01-16       Impact factor: 2.778

4.  Morphometric analysis of the composition of atherosclerotic plaques in the four major epicardial coronary arteries in acute myocardial infarction and in sudden coronary death.

Authors:  A H Kragel; S G Reddy; J T Wittes; W C Roberts
Journal:  Circulation       Date:  1989-12       Impact factor: 29.690

5.  Progression of coronary atherosclerosis in African-American patients.

Authors:  Yu Kataoka; Amy Hsu; Kathy Wolski; Kiyoko Uno; Rishi Puri; E Murat Tuzcu; Steven E Nissen; Stephen J Nicholls
Journal:  Cardiovasc Diagn Ther       Date:  2013-09

6.  Impact of diabetes mellitus on angiographically silent coronary atherosclerosis.

Authors:  Hiroya Tamada; Hideo Nishikawa; Sei Mukai; Morimichi Setsuda; Mamoo Nakamura; Hiroyuki Suzuki; Takahiro Oonishi; Yutaka Kakuta; Alan C Yeung; Takeshi Nakano
Journal:  Circ J       Date:  2003-05       Impact factor: 2.993

7.  Association of kidney function with coronary atherosclerosis and calcification in autopsy samples from Japanese elders: the Hisayama study.

Authors:  Toshiaki Nakano; Toshiharu Ninomiya; Shinji Sumiyoshi; Hiroshi Fujii; Yasufumi Doi; Hideki Hirakata; Kazuhiko Tsuruya; Mitsuo Iida; Yutaka Kiyohara; Katsuo Sueishi
Journal:  Am J Kidney Dis       Date:  2009-09-18       Impact factor: 8.860

8.  Metabolic syndrome and development of diabetes mellitus: application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study.

Authors:  David E Laaksonen; Hanna-Maaria Lakka; Leo K Niskanen; George A Kaplan; Jukka T Salonen; Timo A Lakka
Journal:  Am J Epidemiol       Date:  2002-12-01       Impact factor: 4.897

9.  Prognosis following first acute myocardial infarction in Type 2 diabetes: a comparative population study.

Authors:  P T Donnan; D I R Boyle; J Broomhall; K Hunter; T M MacDonald; R W Newton; A D Morris
Journal:  Diabet Med       Date:  2002-06       Impact factor: 4.359

10.  Differential association between metabolic syndrome and coronary artery disease evaluated with cardiac computed tomography according to the presence of diabetes in a symptomatic Korean population.

Authors:  Ki-Bum Won; Hyuk-Jae Chang; Jimin Sung; Sanghoon Shin; In-Jeong Cho; Chi-Young Shim; Geu-Ru Hong; Young Jin Kim; Byung-Wook Choi; Namsik Chung
Journal:  BMC Cardiovasc Disord       Date:  2014-08-20       Impact factor: 2.298

View more
  2 in total

Review 1.  Assessing Cardiovascular Disease Risk and Responses to Preventive Therapies in Clinical Practice.

Authors:  Kevin C Maki; Mary R Dicklin
Journal:  Curr Atheroscler Rep       Date:  2018-03-20       Impact factor: 5.113

2.  Clinical utility of brain-derived neurotrophic factor as a biomarker with left ventricular echocardiographic indices for potential diagnosis of coronary artery disease.

Authors:  K G Monisha; Paramasivam Prabu; M Chokkalingam; Ram Murugesan; Dragan Milenkovic; Shiek S S J Ahmed
Journal:  Sci Rep       Date:  2020-10-01       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.